| P50 | author | Stanley C Jordan | Q96350303 |
| P2093 | author name string | Kai Cao | |
| | Alice Peng | |
| | Mieko Toyoda | |
| | Ashley A Vo | |
| | Nancy Reinsmoen | |
| | Chih-Hung Lai | |
| | Joseph Kahwaji | |
| | Rafael Villicana | |
| P2860 | cites work | Anti-inflammatory actions of intravenous immunoglobulin | Q28274155 |
| | Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab | Q28274444 |
| | Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine | Q30987740 |
| | A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection | Q32041368 |
| | Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor | Q33335777 |
| | Protective mechanisms of IVIG. | Q33377524 |
| | Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. | Q33379309 |
| | The antiinflammatory IgG. | Q33380416 |
| | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| | Abrogation of anti-HLA antibodies via proteasome inhibition | Q33384617 |
| | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| | Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 |
| | B-cell targeting in rheumatoid arthritis and other autoimmune diseases | Q34514813 |
| | Presensitization: the problem and its management | Q34654726 |
| | Bortezomib: a review of its use in patients with multiple myeloma | Q34980952 |
| | Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. | Q35611406 |
| | Evolution of HLA antibody detection: technology emulating biology | Q35794605 |
| | Renal transplantation at the Johns Hopkins Comprehensive Transplant Center | Q35896457 |
| | Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death | Q35956863 |
| | The effect of desensitization protocols on human splenic B-cell populations in vivo. | Q53575915 |
| | Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. | Q53924174 |
| | Alloantibodies and the outcome of cadaver kidney allografts. | Q53999586 |
| | Overcoming a positive crossmatch in living-donor kidney transplantation. | Q55036659 |
| | Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation | Q57253538 |
| | Pharmacodynamics of Rituximab in Kidney Transplantation | Q62588639 |
| | Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation | Q63916016 |
| | The quality of life in renal transplantation--a prospective study | Q67564896 |
| | The quality of life of patients with end-stage renal disease | Q69938030 |
| | A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants | Q73299691 |
| | Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 |
| | Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report | Q80664944 |
| | Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy | Q80974156 |
| | Antibodies against MICA antigens and kidney-transplant rejection | Q81357717 |
| | Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports | Q81962651 |
| | A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation | Q82026577 |
| | Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients | Q82588311 |
| | Current approaches to treatment of antibody-mediated rejection | Q36135427 |
| | Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors | Q36228422 |
| | Drug insight: rituximab in renal disease and transplantation | Q36577151 |
| | Triggers of inflammation after renal ischemia/reperfusion | Q36634596 |
| | Identification of a receptor required for the anti-inflammatory activity of IVIG. | Q37018736 |
| | Targeting ischemic brain injury with intravenous immunoglobulin | Q37030865 |
| | B cell-directed therapies for autoimmune disease and correlates of disease response and relapse | Q37060811 |
| | Neuroprotection in stroke by complement inhibition and immunoglobulin therapy | Q37091310 |
| | Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. | Q37109070 |
| | Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition | Q37244927 |
| | Modulation of the cellular immune system by intravenous immunoglobulin | Q37300555 |
| | The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells | Q37323152 |
| | Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation | Q37323165 |
| | Antibody-mediated rejection: treatment alternatives and outcomes. | Q37332696 |
| | ABO incompatible renal transplantation: a paradigm ready for broad implementation | Q37454277 |
| | Intravenous immunoglobulin a natural regulator of immunity and inflammation | Q37544139 |
| | Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation | Q38333120 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins | Q40667159 |
| | The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation | Q41609190 |
| | Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection | Q41704096 |
| | Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. | Q42802801 |
| | Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients | Q43705834 |
| | Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients | Q43829155 |
| | Eculizumab for paroxysmal nocturnal haemoglobinuria | Q44109055 |
| | A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 |
| | Rituximab as treatment for refractory kidney transplant rejection | Q44899030 |
| | Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 |
| | Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. | Q45971208 |
| | Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation | Q46077973 |
| | Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant | Q46293120 |
| | Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy | Q46350406 |
| | Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 |
| | Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 |
| | Experience with antibody-mediated rejection in kidney allograft recipients. | Q46683385 |
| | Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report | Q46843837 |
| | Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection | Q46913121 |
| | B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates | Q46927222 |
| | Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive | Q47624655 |
| | Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. | Q47726666 |
| | Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 |
| | Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin | Q50132009 |
| | Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 |
| | Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| | kidney transplantation | Q740909 |
| P304 | page(s) | 2035-45; quiz 2045-8 | |
| P577 | publication date | 2010-01-14 | |
| | 2010-10-01 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Advances in diagnosing and managing antibody-mediated rejection | |
| P478 | volume | 25 | |